Journal article
IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, Influenza, and RSV infections in immunocompromised patients
Clinical infectious diseases
03/02/2026
DOI: 10.1093/cid/ciag114
PMID: 41766454
Abstract
Respiratory viruses-including SARS-CoV-2 (COVID-19), Respiratory Syncytial Virus (RSV), and Influenza-pose significant risks to immunocompromised patients, who experience attenuated vaccine responses and higher morbidity. To address evolving vaccine recommendations for the 2025-2026 season, the Infectious Diseases Society of America (IDSA), in collaboration with the Vaccine Integrity Project (VIP) and partner organizations, developed rapid guidelines for U.S.-licensed vaccines targeting these viruses. The guideline applies to adults and children with compromised immunity due to hematologic malignancy, solid organ or hematopoietic cell transplantation, autoimmune disease on immunosuppressants, HIV with severe immunosuppression, and similar conditions. Strong recommendations, supported by moderate-certainty evidence, endorse timely administration of age-appropriate COVID-19, RSV, and Influenza vaccines, with guidance on optimal timing relative to immunosuppressive therapy and transplantation. Co-administration of these vaccines is considered appropriate. Research gaps remain in immunogenicity, durability, and clinical effectiveness, particularly for patients receiving B-cell-depleting therapies or early post-transplant. Priority areas include defining correlates of protection, optimizing vaccine schedules, evaluating high-dose or adjuvanted formulations, and improving real-world effectiveness and safety data. Equity and access strategies are essential to ensure uptake among vulnerable populations. These guidelines aim to support evidence-based decision-making and highlight the need for harmonized, multi-virus research to inform tailored vaccination strategies for immunocompromised individuals.
Details
- Title: Subtitle
- IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19, Influenza, and RSV infections in immunocompromised patients
- Creators
- Anoma Nellore - NYU Langone HealthPaul Goepfert - University of Alabama at BirminghamChen Sabrina Tan - University of IowaKristina Bajema - Oregon Health & Science UniversityKatherine Belden - Thomas Jefferson UniversityDean Blumberg - University of California, DavisMorgan J Katz - Johns Hopkins UniversityDaniel Kaul - University of Michigan Medical SchoolTanvi Sharma - Boston Children's HospitalShweta Anjan - University of MiamiElla J Ariza-Heredia - The University of Texas MD Anderson Cancer CenterFrancisco Magana - The Ohio State UniversityTimothy Minniear - Le Bonheur Children's HospitalJennifer Loveless - Cadence Design Systems (United States)Dipleen Kaur - Infectious Diseases Society of AmericaElizabeth York - Infectious Diseases Society of AmericaYngve Falck-Ytter - Case Western Reserve UniversityLindsey Baden - Brigham and Women's Hospital
- Resource Type
- Journal article
- Publication Details
- Clinical infectious diseases
- DOI
- 10.1093/cid/ciag114
- PMID
- 41766454
- NLM abbreviation
- Clin Infect Dis
- ISSN
- 1058-4838
- eISSN
- 1537-6591
- Publisher
- Oxford University Press
- Grant note
- Infectious Diseases Society of America
This work was supported by the Infectious Diseases Society of America.
- Language
- English
- Electronic publication date
- 03/02/2026
- Academic Unit
- Microbiology and Immunology; Infectious Diseases; Iowa Neuroscience Institute; Internal Medicine
- Record Identifier
- 9985141896102771
Metrics
3 Record Views